Aptevo Therapeutics, Inc. (APVO)

Aptevo Therapeutics' stock experienced significant events in the past six months. A 1-for-18 reverse stock split on December 26, 2025, caused the stock to plunge. The company reported positive Q3 2025 results, highlighting an 89% remission rate among AML patients treated with mipletamig combinations. Aptevo presented positive Phase 1b/2 RAINIER data for mipletamig at the ASH meeting. Shares fell despite positive interim clinical trial results for mipletamig. Aptevo provided a business update and its 2025 financial results, reiterating positive mipletamig data and announcing a $60 million equity line of credit. Overall, the share price experienced a significant decline of 81.01% between March 27, 2025, and March 26, 2026, and the company is forecast to remain unprofitable over the next three years.

Aptevo Therapeutics, Inc. does not currently have commercialized products, so there is no discernible demand seasonality. Demand will be driven by clinical trial progress, regulatory approvals, and eventual market adoption.

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology and hematology therapeutics. They utilize their ADAPTIR platforms to create bispecific and trispecific immunotherapies for various cancers. Their pipeline includes Mipletamig (APVO436) for AML and MDS, ALG.APV-527 for solid tumors, and several preclinical candidates like APVO603, APVO711, APVO442, APVO451, and APVO452.

Aptevo Therapeutics Inc. is headquartered in Seattle, Washington, and incorporated in Delaware. The company's primary focus for developing immunotherapeutic candidates is in the United States.

Direct information on Aptevo Therapeutics' brand reputation is not explicitly available as a measured metric. Positive clinical trial results for mipletamig enhance the company's scientific and clinical reputation. Stock volatility, financial concerns, and risk factors negatively impact investor confidence and the company's financial reputation. Aptevo faces key risks, including a high probability of bankruptcy, potential clinical trial failures, and extreme share price volatility, which affect overall brand reputation. The company is forecast to remain unprofitable over the next three years.

Aptevo Therapeutics' ownership is a mix of institutional, insider, and retail investors. Institutional shareholders hold varying percentages. Key individual owners include Fuad Elhibri, Scott C. Stromatt, Jane A. Gross, and Grant Grady III.